Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.30%
#3 Glidr Glidr +38.71%
#4 Cysic Cysic +32.50%
#5 Walrus Walrus +23.45%
#6 Tutorial Tutorial +22.66%
#7 Humanity Humanity +17.01%
#8 Enso Enso +16.36%
#9 Codatta Codatta +15.61%
#10 Huma Finance Huma Finance +14.03%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc.

MGTA
Classement en actions #36943
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development... Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.
Prix de l'action
$0.6996
Dernière synchronisation: 2023-09-11
Capitalisation boursière
$2.19M
Changement (1 jour)
-7.74%
Changement (1 an)
0.00%
Pays
US
Échange Magenta Therapeutics, Inc. (MGTA)

Catégorie

Healthcare
Marge opérationnelle de Magenta Therapeutics, Inc. (MGTA)
Marge opérationnelle au 2026 TTM : 0.00%
Selon les derniers rapports financiers et le cours de l'action de Magenta Therapeutics, Inc., la marge opérationnelle actuelle (TTM) est de 0.00%. À la fin de 2026, elle était de 0.00%.
Historique de la marge opérationnelle pour Magenta Therapeutics, Inc. de 2026 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
Pas assez de données pour les dates fournies.
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.